Vacci-Test Corporation

Vacci-Test Corporation

June 10, 2008 08:01 ET

European Approval of VACCI-TEST™ Tetanus

CALGARY, ALBERTA--(Marketwire - June 10, 2008) -

Vacci-Test Corporation ("VTC") of Calgary, Alberta, Canada is pleased to announce that its subsidiary, Vacci-Test Europe, has received the CE mark for its first product, VACCI-TEST™ Tetanus.

VACCI-TEST™ Tetanus is a rapid, sensitive, lateral flow diagnostic test to determine the immune status of an individual by detecting the presence of circulating antibodies. This time saving, precise diagnostic device will allow emergency and point-of-care physicians to determine if a patient needs to be revaccinated.

Since VACCI-TEST™ Tetanus is intended for use as a diagnostic tool in humans the receipt of the CE mark is the last approval step before marketing the product. The CE mark signifies that the product complies with all health, safety and environmental directives of the European Union.

A rapid reliable point-of-care Tetanus test avoids the need and expense of unnecessary revaccination and will play an important role in managing health care expenses in today's cost conscious environment.

Mr. William J. Hogan, Vice-Chairman and Founder of VTC, said "The approval of VACCI-TEST™ Tetanus is the first in a series of product approvals and launches intended for 2008 and demonstrates the company's commitment to delivering value to its shareholders".

VTC is a privately held Canadian company that specializes in second generation magnetic lateral flow tests for the rapid and precise detection and measurement of immune status and infection in animals and humans, and pathogens in food. A key element in VTC's product pipeline is a series of tests for the rapid measurement of pathogens such as E.coli O157:H7 associated with the human food chain.

This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its private filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Vacci-Test Corporation
    Mr. William J. Hogan
    (403) 269-9424 or Toll Free: 1-877-298-0208
    Vacci-Test Corporation
    Media Inquiries:
    Honourable Charlie Mayer
    Director of Corporate Development
    (403) 269-9424 or Toll Free: 1-877-298-0208
    Vacci-Test Corporation
    Suite 1005, 550 - 11th Avenue, SW
    Calgary, Alberta. T2R 1M7